At MDS 2020, researchers presented findings from part 1 of a two-part trial of prasinezumab in patients with early Parkinson’s disease (PD).
Prasinezumab is a humanized monoclonal antibody designed to target α‐synuclein, with the aim of reducing neuronal toxicity and blocking the spread of pathogenic α‐synuclein aggregates.